Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : ALTA NATURAL HERBS & SUPPLEMENTS LTD. (AHS-ASE) -- Ignore unavailable to you. Want to Upgrade?

To: JDW who wrote (36)	11/16/1998 2:05:00 PM
From: Abbeydale	Read Replies (1) \| Respond to of 66

This just out: Hepatitis C breakthrough now available in Canada Alta Natural Herbs & Supplements Ltd AHS Shares issued 14,391,333 Nov 13 close $0.98 Mon 16 Nov 98 News Release Mr. Adolf Huckschlag reports Following extensive international clinical and preclinical trials, Alta Natural Herbs & Supplements will now begin distribution of Hepatico in Canada. Upon reviewing 17 independent reports regarding the effectiveness of Hepatico on Hep-C, Alta Natural Herbs & Supplements launched independent human tests in Canada and the United States. Preliminary results have confirmed the overseas findings. Administered orally in capsule form, Hepatico is a nutraceutical product containing extracts of the nettle, plantain and immortelle herbs, in combination with other naturally occurring active ingredients from the Russian Republic of Georgia. Based upon the examination of the preliminary results and after comparisons to the European scientific data conducted between 1992 and 1996, Alta Natural Herbs & Supplements is verifying the validity of the effectiveness of Hepatico as a primary therapy for persons suffering from toxic and viral liver dysfunction.

To: JDW who wrote (36)	11/17/1998 10:25:00 PM
From: reg	Respond to of 66

To: reg (34 ) From: JDW Sunday, Nov 15 1998 2:18PM ET Reply # of 60 Reg, Your question identifies you as woefully uninformed and possibly without the initiative or capacity to do the most basic research. Well I may be both but I hope my question stopped some people from buying this stock. With the controversy over compensation to Hep sufferers in Canada this stock would have been at $50 if legit.